Oxybutynin Gel for Pediatric Overactive Bladder

"Oxybutynin is a common pharmaceutical used to manage urinary urge incontinence, as well as certain neurological conditions and detrusor hyperreflexia."

"This study seeks 58 minors aged 3 to 16 who have a neurogenic bladder. Participants must meet the following criteria: age range of 3 to <17, neurological condition requiring CIC (clean intermittent catheterization)."

"Oxybutynin was initially studied in 2011 at Cedars-Sinai Medical Center-West Hollywood. Since then, 52 trials have concluded with a further 5 now recruiting patients primarily located in Milwaukee, Wisconsin."

"Based on the study's inclusion criteria, 3 year olds and adolescents up to 16 years old can be enrolled in this trial."

"The current sites enrolling patients for this trial are situated in 17 different cities, with notable spots being Milwaukee, Loma Linda and Los Angeles. For the comfort of participants it is highly recommended to join a site close by them so as to minimize travel requirements."

"Owing to the Phase 4 status, which confirms Oxybutynin's approval, our team at Power assign this medication a safety score of 3."

"In order to initiate the trial, AbbVie is required to recruit 58 participants who fit its inclusion criteria. Enrollment will be managed at two sites: Children's Hospital Wisconsin - Milwaukee Campus /ID# 245783 in Milwaukee, Wisconsin and Loma Linda University Health in Loma Linda, California."

"Affirmative. According to clinicaltrials.gov, this study is actively seeking volunteers for its trial which was first published on May 2nd 2011 and most recently amended on November 9th 2022. The research team needs 58 patients across 17 medical centres."

"Oxybutynin has been studied since 2011, when AbbVie first sponsored its initial trial. With the conclusion of this 58-patient study in 2011, Oxybutynin was granted Phase 4 drug approval and is now being tested across 102 cities throughout two countries via 5 different trials."